(Q37214866)

English

Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen

scientific article published on September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

1 reference

Europe PubMed Central

Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Jaffer A Ajani

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

language of work or name

0 references

publication date

1 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

113

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

945-955

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Epidemiology of gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

21 January 2018

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

21 January 2018

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Perspectives in the treatment of gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity of platinum compounds

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Is oxaliplatin the optimal platinum agent in gastric cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23661

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23661

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37214866&oldid=2127774789"